Showing results (621-630 of 1,651) with videos related to

Sort By:
Pageof 166
Hepatology International|May 13, 2022
Automated fibrosis phenotyping of liver tissue from non-tumor lesions of patients with and without hepatocellular carcinoma after liver transplantation for non-alcoholic fatty liver diseaseYutaka Nakamura, Hisamitsu Miyaaki, Satoshi Miuma, et al.
Hepatology International|June 3, 2021
Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular diseaseJi Hye Park, Bo Kyung Koo, Won Kim, et al.
Hepatology International|June 2, 2021
Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver diseaseRafael Paternostro, Katharina Staufer, Stefan Traussnigg, et al.
Hepatology International|June 26, 2021
Comparative accuracy of prognostic models for short-term mortality in acute-on-chronic liver failure patients: CAP-ACLFNipun Verma, Radha Krishan Dhiman, Virendra Singh, et al.
Hepatology International|December 6, 2019
Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imagingSunyoung Lee, Myeong-Jin Kim, Seung-Seob Kim, et al.
Hepatology International|September 29, 2020
Efficacy of peg-interferon-nucleoside analog sequential optimization therapy in HBeAg-positive patients with CHBWei Xu, Qiang Li, Chenlu Huang, et al.
Hepatology International|January 3, 2021
Noninvasive assessment of liver fibrosis for predicting acute-on-chronic liver failure in patients with chronic hepatitis BFangwan Yang, Yujuan Liu, Baimei Zeng, et al.
Hepatology International|October 31, 2020
Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trialXiaoke Li, Daqiao Zhou, Xiaoling Chi, et al.
Hepatology International|September 8, 2022
Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumabTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Hepatology International|September 24, 2022
N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLDLiang-Jie Tang, Gang Li, Mohammed Eslam, et al.
Pageof 166